Trial Profile
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 15 May 2014 New trial record